(Q37302639)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

T. Scott Stroup

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

14

Jeffrey A Lieberman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

5

Robert A Rosenheck

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Stanley N Caroff

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Vicki G Davis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Sonia M Davis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Joseph P McEvoy

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

E Cabrina Campbell

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Bruce L Saltz

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Silvana Riggio

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Miranda H Chakos

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Marvin S Swartz

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Richard S E Keefe

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

CATIE Investigators

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

10 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

The Journal of Clinical Psychiatry

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

295-303

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia

13 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Extrapyramidal side-effects of antipsychotics in a randomised trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Clozapine withdrawal-emergent dystonias and dyskinesias: a case series

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Treatment of tardive dyskinesia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Therapeutic strategies against tardive dyskinesia. Two decades of experience

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

The positive and negative syndrome scale (PANSS) for schizophrenia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

The two-syndrome concept: origins and current status

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

A rating scale for drug-induced akathisia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

The effects of clozapine on tardive dyskinesia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Clozapine in tardive dyskinesia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

A rating scale for extrapyramidal side effects

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

The prediction of chronic persistent versus intermittent tardive dyskinesia. A retrospective follow-up study.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Mortality rates among patients with schizophrenia and tardive dyskinesia

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Baseline neurocognitive deficits in the CATIE schizophrenia trial.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825701

Tardive dyskinesia status: stability or change

2 September 2018

1 reference

12 December 2020

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study

1 reference

12 December 2020

Tardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlates of Remission and Persistence

1 reference

12 December 2020

Ten-year outcome of tardive dyskinesia

1 reference

12 December 2020

Clozapine in tardive dyskinesia: observations from human and animal model studies

1 reference

12 December 2020

Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

12 December 2020

Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study

1 reference

12 December 2020

The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up

1 reference

12 December 2020

Abnormal Movements and Prognosis in Schizophrenia

1 reference

12 December 2020

Research Diagnoses for Tardive Dyskinesia

1 reference

12 December 2020

Tardive dyskinesia: a 3-year follow-up study

1 reference

12 December 2020

One year follow-up of tardive dyskinesia

1 reference

12 December 2020

Integrating incidence and prevalence of tardive dyskinesia

1 reference

12 December 2020

Identifiers

DOI

10.4088/JCP.09M05793YEL

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20816031%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

PubMed publication ID

20816031

1 reference